Clinical Policy: Implantable Hormone Pellets Reference Number: CA.CP.MP.507

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Clinical Policy: Implantable Hormone Pellets Reference Number: CA.CP.MP.507"

Transcription

1 Clinical Policy: Reference Number: CA.CP.MP.507 Effective Date: 1/12 Last Review Date: 7/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Implantable hormone pellets have been investigated as an alternative to hormone replacement via other routes. The biodegradable pellets are implanted underneath the skin (e.g. abdomen, buttocks) and must be reimplanted at specific intervals depending on the hormone implanted, dosage, and rate of release. Policy/Criteria I. It is the policy of Health Net of California that implantable testosterone pellets (e.g. Testopel pellets) are medically necessary for the following indications: A. As a replacement therapy for males with conditions associated with a deficiency or absence of endogenous testosterone, specifically, for either of the following situations when there has been a failure or intolerance of topical (e.g. patch, gels) and injectable testosterone: 1. Congenital or acquired hypogonadism (i.e., testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome, or orchidectomy); 4 OR 2. Congenital or acquired hypogonadotrophic hypogonadism (i.e., idiopathic or gonadotrophic luteinizing hormone-releasing hormone deficiency, or pituitaryhypothalamic injury from tumors, trauma or radiation). 4 **Note: If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment would be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. 4 II. It is the policy of Health Net of California that implantable testosterone pellets are investigational for any other circumstances than those specified above, including for routine use in older men with low testosterone levels, due to inconclusive evidence in the peer reviewed studies regarding its potential benefits. 10 III. It is the policy of Health Net of California that implantable estradiol pellets are investigational. There are no U.S. FDA approved estradiol pellets for subcutaneous implantation available in the United States. 1 Background Testosterone Deficiency Testosterone deficiency has become a growing concern in the field of men's sexual health, with more men presenting for evaluation of this condition. This has caused increased use of subcutaneous testosterone pellets for the treatment of hypogonadism since the introduction of Page 1 of 6

2 Testopel in 2008 by Slate Pharmaceuticals (Durham, NC, USA). The dosage of Testopel is 3-6 (75 mg) pellets every 3-6 months. Adverse events include pellet extrusion, infection and fibrosis. 8 Androgens may be used cautiously to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder. Therefore, puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be taken every 6 months to assess the effect of treatment on epiphyseal centers. 2 Endocrine Society Recommends the following: Testosterone therapy for men with unequivocally low serum testosterone levels, symptomatic androgen deficiency to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density. Against starting testosterone therapy in patients with breast or prostate cancer, a palpable prostate nodule or induration or prostate-specific antigen greater than 4 ng/ml or greater than 3 ng/ml in men at high risk for prostate cancer. This would include African Americans or men with first-degree relatives with prostate cancer without further urological evaluation, hematocrit > 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms with International Prostate SymptomScore > 19, or uncontrolled or poorly controlled heart failure. 9 Studies have noted that subcutaneous testosterone pellets are a viable treatment option for hypogonadal men seeking a convenient and efficacious alternative modality of testosterone replacement therapy. 3 Bioidentical hormones Menopausal therapy has been provided not only by commercially available products but also by compounding. This refers to creation of an individualized preparation in response to a health care provider s prescription to create a medication tailored to the specialized needs of an individual patient. This would include compounded bioidentical hormone therapy. 5 Bioidentical hormones are plant-derived hormones that are chemically similar or structurally identical to those produced by the body. Many compounding pharmacies use the term bioidentical hormone to imply that these preparations are natural or the same as endogenous substances and, thus, are safe. The phrase bioidentical hormone therapy has been recognized by the FDA and the Endocrine Society as a marketing term and not one based on scientific evidence. 1 Page 2 of 6

3 Subcutaneous implantable pellets made up of estradiol, estrogen, or testosterone in combination with estrogen or estradiol have been custom compounded according to physician specifications. However, none of these are FDA approved for U.S. distribution and their safety and efficacy has not been adequately demonstrated in well-designed clinical trials. 1 The FDA requires manufacturers of FDA-approved products that contain estrogen and progesterone to use class labeling (i.e. the black box warning indicating a drug with special problems, particularly ones that may lead to death or serious injury) reflective of the findings of the Women s Health Initiative. 12 American College of Obstetricians and Gynecologists Evidence is lacking to support superiority claims of compounded bioidentical hormones over conventional menopausal hormone therapy. Conventional hormone therapy is preferred over compounded hormone therapy given the available data. 1 Endocrine Society There is no rationale for routine prescribing of unregulated, untested, and potentially harmful custom compounded bioidentical hormone therapies. 7 Coding Implications This clinical policy references Current Procedural Terminology (CPT ). CPT is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2017, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services. CPT Description Codes Subcutaneous hormone pellet implantation (implantation of estradiol and/or testosterone pellets beneath the skin) Insertion, non-biodegradable drug delivery implant Chorionic gonadotropin stimulation panel; testosterone response This panel must include the following: Testosterone (84403 x 2 on 3 pooled blood samples) Chorionic gonadotropin stimulation panel; estradiol response This panel must include the following: Estradiol (82670 x 2 on 3 pooled blood samples) Estradiol Testosterone; free Testosterone; total Testosterone; bioavailable, direct measurement (eg, differential precipitation) Page 3 of 6

4 HCPCS Description Codes S1089 Testosterone pellet, 75 mg ICD-10-CM Diagnosis Codes that Support Coverage Criteria ICD-10-CM Description Code E29.1-E29.1 Testicular hypofunction E30.0 Delayed puberty Q53.01-Q53.22 Undescended and ectopic testicles N44.0-N44.02 Torsion of testes N45.2 Orchitis Reviews, Revisions, and Approvals Date Approval Date Policy Adopted from Health Net NMP #507 7/17 References 1. American College of Obstetricians and Gynecologists (ACOG). Compounded Bioidentical Hormones. Number 322. Reaffirmed Crowley WF, Pitteloud N. Diagnosis and treatment of delayed puberty. UpToDate. March 3, Guo C, Gu W, Liu M, et al. Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials. Exp Ther Med Mar;11(3): Hayes. Search & Summary. Testopel Implantable Testosterone Pellets (Endo Pharmaceuticals Inc.) for Hypogonadism. June 1, Hayes. Health Technology Brief. Subcutaneous Implantation of Estradiol Pellets for Postmenopausal Disorders. December 24, Archived January 26, Martin KA, Barbieri RL. Treatment of menopausal symptoms with hormone therapy. UpToDate. April 19, Santoro N, Braunstein GD, Butts CL, et al. Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab Apr; 101(4): Snyder P. Testosterone treatment of male hypogonadism. UpToDate. April 12, The Endocrine Society Clinical Guideline. Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes. J Clin Endocrinol Metab, June 2010, 95(6): U.S. FDA. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. January U.S.. FDA. FDA Approved Drug Products. Testopel U.S. FDA. Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women. May 31, Updated Page 4 of 6

5 Important Reminder This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. Health Plan means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan s affiliates, as applicable. The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures. This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time. This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions. Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan. This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members Page 5 of 6

6 and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services. Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy. Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at for additional information Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene and Centene Corporation are registered trademarks exclusively owned by Centene Corporation. Page 6 of 6

Clinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:

Clinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: Clinical Policy: (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 07.25.17 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder

More information

Clinical Policy: Digital Breast Tomosynthesis Reference Number: CP.MP.90

Clinical Policy: Digital Breast Tomosynthesis Reference Number: CP.MP.90 Clinical Policy: Reference Number: CP.MP.90 Effective Date: 01/18 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Robotic Surgery Reference Number: CP.MP. 207

Clinical Policy: Robotic Surgery Reference Number: CP.MP. 207 Clinical Policy: Robotic Surgery Reference Number: CP.MP. 207 Effective Date: 03/05 Last Review Date: 10/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16 Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16 Last Review Date: 02/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517 Clinical Policy: Implantable Miniature Telescope for Age Related Macular Reference Number: CP.MP.517 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important

More information

Clinical Policy: Homocysteine Testing Reference Number: CP.MP.121

Clinical Policy: Homocysteine Testing Reference Number: CP.MP.121 Clinical Policy: Reference Number: CP.MP.121 Effective Date: 08/16 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Fecal Calprotectin Assay Reference Number: CP.MP.135

Clinical Policy: Fecal Calprotectin Assay Reference Number: CP.MP.135 Clinical Policy: Reference Number: CP.MP.135 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Essure Removal Reference Number: CP.MP.131

Clinical Policy: Essure Removal Reference Number: CP.MP.131 Clinical Policy: Reference Number: CP.MP.131 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Cochlear Implant Replacements Reference Number: CP.MP.14

Clinical Policy: Cochlear Implant Replacements Reference Number: CP.MP.14 Clinical Policy: Reference Number: CP.MP.14 Effective Date: 02/09 Last Review Date: 09/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Total Artificial Heart Reference Number: CP.MP.127

Clinical Policy: Total Artificial Heart Reference Number: CP.MP.127 Clinical Policy: Reference Number: CP.MP.127 Effective Date: 12/16 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145

Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145 Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145 Effective Date: 05/17 Last Review Date: 06/17 See Important Reminder at the end of this policy for important regulatory

More information

Clinical Policy: Bone-Anchored Hearing Aid Reference Number: CP.MP.93

Clinical Policy: Bone-Anchored Hearing Aid Reference Number: CP.MP.93 Clinical Policy: Reference Number: CP.MP.93 Effective Date: 12/13 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441

Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441 Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441 Effective Date: November 2008 Last Review Date: January 2017 See Important Reminder at the

More information

Clinical Policy: Helicobacter Pylori Serology Testing Reference Number: CP.MP.153

Clinical Policy: Helicobacter Pylori Serology Testing Reference Number: CP.MP.153 Clinical Policy: Reference Number: CP.MP.153 Effective Date: 12/17 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Ustekinumab (Stelara) Reference Number: CP.PHAR.264

Clinical Policy: Ustekinumab (Stelara) Reference Number: CP.PHAR.264 Clinical Policy: (Stelara) Reference Number: CP.PHAR.264 Effective Date: 08/16 Last Review Date: 05/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Clinical Policy: Fertility Preservation Reference Number: CP.MP.130

Clinical Policy: Fertility Preservation Reference Number: CP.MP.130 Clinical Policy: Reference Number: CP.MP.130 Effective Date: 9/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Growing Rods Spinal Surgery Reference Number: CP.MP.354

Clinical Policy: Growing Rods Spinal Surgery Reference Number: CP.MP.354 Clinical Policy: Growing Rods Spinal Surgery Reference Number: CP.MP.354 Effective Date: 06/07 Last Review Date: 10/16 Coding Implications Revision Log See Important Reminder at the end of this policy

More information

Clinical Policy: Ambulatory Electroencephalography Reference Number: CP.MP.96

Clinical Policy: Ambulatory Electroencephalography Reference Number: CP.MP.96 Clinical Policy: Ambulatory Electroencephalography Reference Number: CP.MP.96 Effective Date: 09/15 Last Review Date: 09/17 See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Refractive Surgery Reference Number: CP.MP. 391

Clinical Policy: Refractive Surgery Reference Number: CP.MP. 391 Clinical Policy: Refractive Surgery Reference Number: CP.MP. 391 Effective Date: November 2007 Last Review Date: January 2016 Coding Implications Revision Log See Important Reminder at the end of this

More information

Clinical Policy: Functional MRI Reference Number: CP.MP.43

Clinical Policy: Functional MRI Reference Number: CP.MP.43 Clinical Policy: Reference Number: CP.MP.43 Effective Date: 09/09 Last Review Date: 10/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Fractional Exhaled Nitric Oxide Reference Number: CP.MP.103

Clinical Policy: Fractional Exhaled Nitric Oxide Reference Number: CP.MP.103 Clinical Policy: Reference Number: CP.MP.103 Effective Date: 01/16 Last Review Date: 01/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Posterior Tibial Nerve Stimulation for Voiding Dysfunction Reference Number: CP.MP.133

Clinical Policy: Posterior Tibial Nerve Stimulation for Voiding Dysfunction Reference Number: CP.MP.133 Clinical Policy: Reference Number: CP.MP.133 Effective Date: 10/16 Last Review Date: 10/16 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications

More information

Clinical Policy: Microvolt T-Wave Alternans Testing Reference Number: CP.MP.212

Clinical Policy: Microvolt T-Wave Alternans Testing Reference Number: CP.MP.212 Clinical Policy: Reference Number: CP.MP.212 Effective Date: 03/05 Last Review Date: 09/17 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Sandostatin, Sandostatin LAR Depot) Reference Number: CP.PHAR.40 Effective Date: 03.01.10 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log

More information

Clinical Policy: Infertility Therapy Reference Number: CP.CPA.261 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal

Clinical Policy: Infertility Therapy Reference Number: CP.CPA.261 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal Clinical Policy: Reference Number: CP.CPA.261 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Probuphine, Sublocade) Reference Number: CP.PHAR.289 Effective Date: 11.16.16 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the

More information

Clinical Policy: Brentuximab Vedotin (Adcetris) Reference Number: CP.PHAR.303

Clinical Policy: Brentuximab Vedotin (Adcetris) Reference Number: CP.PHAR.303 Clinical Policy: (Adcetris) Reference Number: CP.PHAR.303 Effective Date: 02/17 Last Review Date: 02/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322

Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322 Clinical Policy: (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 03/17 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Clinical Policy: Oxygen Therapy in the Home Reference Number: CP.MP.485

Clinical Policy: Oxygen Therapy in the Home Reference Number: CP.MP.485 Clinical Policy: Reference Number: CP.MP.485 Effective Date: 09/04 Last Review Date: 09/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: 05.16.17 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy

More information

Clinical Policy: Ultrafiltration for Heart Failure Reference Number: CP.MP.456

Clinical Policy: Ultrafiltration for Heart Failure Reference Number: CP.MP.456 Clinical Policy: Reference Number: CP.MP.456 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.PMN.04 Effective Date: 11.15.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Voice Therapy Reference Number: CP.MP.HN 134

Clinical Policy: Voice Therapy Reference Number: CP.MP.HN 134 Clinical Policy: Reference Number: CP.MP.HN 134 Effective Date: 4/10 Last Review Date: 09/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Enstilar, Sernivo, Taclonex) Reference Number: CP.CPA.255 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end

More information

Clinical Policy: Heart-Lung Transplant Reference Number: CP.MP.132

Clinical Policy: Heart-Lung Transplant Reference Number: CP.MP.132 Clinical Policy: Reference Number: CP.MP.132 Effective Date: 06/17 Last Review Date: 06/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at

More information

Androderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo

Androderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical

More information

Clinical Policy: Lysis of Epidural Lesions Reference Number: CP.MP.116

Clinical Policy: Lysis of Epidural Lesions Reference Number: CP.MP.116 Clinical Policy: Reference Number: CP.MP.116 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Acupuncture Reference Number: CP.MP.92

Clinical Policy: Acupuncture Reference Number: CP.MP.92 Clinical Policy: Reference Number: CP.MP.92 Effective Date: 12/13 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Dalteparin (Fragmin) Reference Number: CP.PHAR.225

Clinical Policy: Dalteparin (Fragmin) Reference Number: CP.PHAR.225 Clinical Policy: (Fragmin) Reference Number: CP.PHAR.225 Effective Date: 05/16 Last Review Date: 05/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Testosterone Injection and Implant

Testosterone Injection and Implant Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone

More information

Clinical Policy: Pazopanib (Votrient) Reference Number: CP.PHAR.81 Effective Date: 10/11

Clinical Policy: Pazopanib (Votrient) Reference Number: CP.PHAR.81 Effective Date: 10/11 Clinical Policy: (Votrient) Reference Number: CP.PHAR.81 Effective Date: 10/11 Last Review Date: 12/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date:

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date: Clinical Policy: (Zoladex) Reference Number: ERX.SPA.145 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Disc Decompression Procedures Reference Number: CP.MP.114

Clinical Policy: Disc Decompression Procedures Reference Number: CP.MP.114 Clinical Policy: Reference Number: CP.MP.114 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Allogenic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-thalassemia

Clinical Policy: Allogenic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-thalassemia Clinical Policy: Allogenic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-thalassemia Reference Number: CP.MP.108 Effective Date: 03/16 Last Review Date: 03/17 See Important Reminder at the

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Prolia, Xgeva) Reference Number: CP.PHAR.58 Effective Date: 03.01.11 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Rayos) Reference Number: CP.CPA.273 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283

Clinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283 Clinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important

More information

Clinical Policy: Pemetrexed (Alimta) Reference Number: CP.PHAR.368 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Pemetrexed (Alimta) Reference Number: CP.PHAR.368 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Alimta) Reference Number: CP.PHAR.368 Effective Date: 10.31.17 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (DDAVP, Noctiva, Stimate) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 05/02/17 Last Review Date: 05/17 Line of Business: Medicaid - HNMC Revision Log See Important Reminder

More information

Clinical Policy: Endometrial Ablation Reference Number: CP.MP.106

Clinical Policy: Endometrial Ablation Reference Number: CP.MP.106 Clinical Policy: Reference Number: CP.MP.106 Effective Date: 02/16 Last Review Date: 09/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory and

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Reclast, Zometa) Reference Number: CP.PHAR.59 Effective Date: 03.11 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Willebrand Factor Complex (Human - Alphanate, Humate-P, Wilate) Reference Number: ERX.SPA.185 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the

More information

Clinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Repatha) Reference Number: CP.CPA.269 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Testosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder

Testosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.37 Subject: Testosterone Powder Page: 1 of 11 Last Review Date: September 18, 2015 Testosterone powder

More information

Clinical Policy: Urodynamic Testing Reference Number: CP.MP.98

Clinical Policy: Urodynamic Testing Reference Number: CP.MP.98 Clinical Policy: Reference Number: CP.MP.98 Effective Date: 10/15 Last Review Date: 10/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Vosevi) Reference Number: CP.HNMC.41 Effective Date: 07.26.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Clinical Policy: Colchicine (Colcrys) Reference Number: CP.PPA.11. Line of Business: Medicaid

Clinical Policy: Colchicine (Colcrys) Reference Number: CP.PPA.11. Line of Business: Medicaid Clinical Policy: (Colcrys) Reference Number: CP.PPA.11 Effective Date: 05/11 Last Review Date: 05/176 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this

More information

Original Policy Date

Original Policy Date MP 5.01.30 Implantable Hormone Pellets Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy created with literature search/12:2013 Return

More information

Clinical Policy: Diagnosis of Vaginitis Reference Number: CP.MP.97

Clinical Policy: Diagnosis of Vaginitis Reference Number: CP.MP.97 Clinical Policy: Reference Number: CP.MP.97 Effective Date: 06/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date: Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers Reference Number: CP.MP. 346

Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers Reference Number: CP.MP. 346 Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Reference Number: CP.MP. 346 Effective Date: 11/15 Last Review Date: 11/17 See Important Reminder at the end of this policy

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: Last Review Date: 01/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder

More information

Policy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043.

Policy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043. Cellular Immunotherapy forr Prostate Cancer Policy Number: 8.01.53 Origination: 11/2010 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for cellular immunotherapy for prostate

More information

Clinical Policy: Outpatient Testing for Drugs of Abuse Reference Number: CP.MP.HN 542

Clinical Policy: Outpatient Testing for Drugs of Abuse Reference Number: CP.MP.HN 542 Clinical Policy: Reference Number: CP.MP.HN 542 Effective Date: 09/12 Last Review Date: 9/17 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications

More information

Clinical Policy: Neonatal Abstinence Syndrome Guidelines Reference Number: CP.MP.86 Effective Date: 10/13

Clinical Policy: Neonatal Abstinence Syndrome Guidelines Reference Number: CP.MP.86 Effective Date: 10/13 Clinical Policy: Reference Number: CP.MP.86 Effective Date: 10/13 Last Review Date: 10/17 See Important Reminder at the end of this policy for important regulatory and legal information. Revision Log Description

More information

denosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017

denosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017 Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Based on review of available data, the Company may consider the use of denosumab (Prolia) for the

Based on review of available data, the Company may consider the use of denosumab (Prolia) for the Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Clinical Policy: Diagnosis of Vaginitis Reference Number: CP.MP.97

Clinical Policy: Diagnosis of Vaginitis Reference Number: CP.MP.97 Clinical Policy: Reference Number: CP.MP.97 Effective Date: 06/16 Last Review Date: 06/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

RETIRED. Maximum Drug Dose Policy

RETIRED. Maximum Drug Dose Policy RETIRED DRUG POLICY Policy Number 2017D0034A Maximum Drug Dose Policy Annual Approval Date 3/1/2017 Approved By UnitedHealthcare National Pharmacy & Therapeutics Committee United Healthcare Community Plan

More information

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: January 1, Related Policies None

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: January 1, Related Policies None DRUG TESTING POLICY UnitedHealthcare Oxford Reimbursement Policy Policy Number: ADMINISTRATIVE 259.2 T0 Effective Date: January 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 APPLICABLE LINES

More information

Clinical Policy: Optic Nerve Decompression Surgery Reference Number: CP.MP.128

Clinical Policy: Optic Nerve Decompression Surgery Reference Number: CP.MP.128 Clinical Policy: Reference Number: CP.MP.128 Effective Date: 09/16 Last Review Date: 09/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: October 1, Related Policies None

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: October 1, Related Policies None DRUG TESTING POLICY UnitedHealthcare Oxford Reimbursement Policy Policy Number: ADMINISTRATIVE 259.1 T0 Effective Date: October 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 APPLICABLE LINES

More information

6/14/2010. GnRH=Gonadotropin-Releasing Hormone.

6/14/2010. GnRH=Gonadotropin-Releasing Hormone. Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Testosterone Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 7 References... 7 Effective Date... 1/1/2018

More information

Clinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127

Clinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127 Clinical Policy: (Avastin) Reference Number: ERX.SPMN.127 Effective Date: 03/14 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Medical Necessity Guidelines: Transgender Surgical Procedures

Medical Necessity Guidelines: Transgender Surgical Procedures Medical Necessity Guidelines: Transgender Surgical Procedures Effective: September 13, 2017 Clinical Documentation and Prior Authorization Required Applies to: Coverage Guideline, No Prior Authorization

More information

Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension)

Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension) Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension) Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management

More information

Name of Policy: Boniva (Ibandronate Sodium) Infusion

Name of Policy: Boniva (Ibandronate Sodium) Infusion Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews

More information

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL Policy Number: PA.018.MH Last Review Date: 08/04/2016 Effective Date: 01/01/2017

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL Policy Number: PA.018.MH Last Review Date: 08/04/2016 Effective Date: 01/01/2017 MedStar Health, Inc. POLICY AND PROCEDURE MANUAL PA.018.MH Infertility- Treatment This policy applies to the following lines of business: MedStar Employee (Select) MedStar MA DSNP CSNP (Not Covered) MedStar

More information

Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary

Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series

More information

2017 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1

2017 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1 GE Healthcare 2017 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1 February 2017 www.gehealthcare.com/reimbursement This advisory addresses Medicare coding, coverage and

More information

Uphold LITE Vaginal Support System 2015 Coding & Quick Reference Guide

Uphold LITE Vaginal Support System 2015 Coding & Quick Reference Guide Hospital Outpatient Coding Scenarios This guide contains specific information for two (2) common coding/reimbursement scenarios related to the use of the Uphold LITE Vaginal Support System when performed

More information

2015 Facility and Physician Billing Guide Heart Valve Technologies

2015 Facility and Physician Billing Guide Heart Valve Technologies 2015 Facility and Physician Billing Guide Heart Valve Technologies PHYSICIAN BILLING CODES Clinicians use Current Procedural Terminology (CPT 1 ) codes to bill for procedures and services. Each CPT code

More information

Topical Oxygen Wound Therapy (MEDICAID)

Topical Oxygen Wound Therapy (MEDICAID) Topical Oxygen Wound Therapy (MEDICAID) Last Review Date: September 8, 2017 Number: MG.MM.DM.15C8v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or

More information

GUIDELINES: PEER REVIEW TRAINING BOD G [Amended BOD ; BOD ; BOD ; Initial BOD ] [Guideline]

GUIDELINES: PEER REVIEW TRAINING BOD G [Amended BOD ; BOD ; BOD ; Initial BOD ] [Guideline] GUIDELINES: PEER REVIEW TRAINING BOD G03-05-15-40 [Amended BOD 03-04-17-41; BOD 03-01-14-50; BOD 03-99-15-48; Initial BOD 06-97-03-06] [Guideline] I. Purpose Guidelines: Peer Review Training provide direction

More information

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy? Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force

More information

Bone Mineral Density Studies in Adult Populations

Bone Mineral Density Studies in Adult Populations Bone Mineral Density Studies in Adult Populations Last Review Date: July 14, 2017 Number: MG.MM.RA10aC6 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy TENS (Transcutaneous Electrical Nerve Stimulator) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tens_(transcutaneous_electrical_nerve_stimulator) 7/1982

More information

CHAPTER NINE INSULIN AND GLUCAGON ADMINISTRATION

CHAPTER NINE INSULIN AND GLUCAGON ADMINISTRATION CHAPTER NINE INSULIN AND GLUCAGON ADMINISTRATION SECTION I PURPOSE AND AUTHORITY A. REGULATORY AUTHORITY 1. These rules shall be known as the Arkansas Department of Education and Arkansas State Board of

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): July 26, 2011 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at

More information

MolDX: HLA-DQB1*06:02 Testing for Narcolepsy

MolDX: HLA-DQB1*06:02 Testing for Narcolepsy MolDX: HLA-DQB1*06:02 Testing for Narcolepsy CGS Administrators, LLC Jump to Section... Please Note: This is a Proposed LCD. Proposed LCDs are works in progress and not necessarily a reflection of the

More information

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR

More information

CERT Oxygen Errors: The DME CERT Outreach and Education Task Force Responds

CERT Oxygen Errors: The DME CERT Outreach and Education Task Force Responds CERT Oxygen Errors: The DME CERT Outreach and Education Task Force Responds DME CERT Outreach and Education Task Force National Oxygen Webinar, July 22, 2014 1 Today s Presenters Michael Hanna, CERT Task

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Daklinza) Reference Number: CP. HNMC.44 Effective Date: 11.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Answers to Your Questions on Bioidentical Hormone Therapy

Answers to Your Questions on Bioidentical Hormone Therapy Answers to Your Questions on Bioidentical Hormone Therapy Question #1: What is bioidentical hormone therapy? There is no real scientific definition for bioidentical hormones, because this term originated

More information

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR

More information